We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.50 | 0.27% | 1,655.50 | 1,655.00 | 1,656.00 | 1,661.50 | 1,650.00 | 1,656.50 | 706,950 | 12:23:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.81 | 68.05B |
Date | Subject | Author | Discuss |
---|---|---|---|
27/8/2019 08:50 | All the gains made on the good news have now evaporated | abdullla | |
23/8/2019 10:02 | Good news. "GlaxoSmithKline was in the green after the pharmaceuticals giant said a clinical trial of its blood cancer treatment met its primary goal." Morning everyone. | philanderer | |
23/8/2019 08:58 | Bailed out. No easy route back in.Lots of patience required now. | xxxxxy | |
23/8/2019 08:41 | Right now, 1650p looks attractive! | tradermichael | |
23/8/2019 08:30 | TM,what do you think the bargain price is | abdullla | |
23/8/2019 08:14 | Too much good news about to get a bargain price at the moment: GlaxoSmithKline PLC (GSK.LN) said Friday that headline results from its DREAMM-2 study for treatment of multiple myeloma, a type of blood cancer, were positive. The pharmaceutical company said the two-arm study of its treatment belantamab mafodotin met its primary objective and demonstrated a clinically meaningful overall response rate. Safety and tolerability was consistent with that observed in the DREAMM-1 study, GlaxoSmithKline said. Data from the DREAMM-2 study will be the basis for regulatory filings starting later this year, the company said. Belantamab mafodotin is on track for regulatory submission by the end of 2019, it said. | tradermichael | |
23/8/2019 08:03 | Buy now or you miss the train | abdullla | |
22/8/2019 17:08 | No-one buying anywhere | prambigear | |
22/8/2019 09:26 | GSK going up but no one buying here | abdullla | |
21/8/2019 11:18 | GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a Japanese New Drug Application (JNDA) to the Ministry of Health, Labour and Welfare seeking marketing approval for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with renal anaemia due to chronic kidney disease (CKD). Dr Hal Barron, Chief Scientific Officer and President R&D, GSK said, “Around 3.5 million patients in Japan have anaemia associated with renal disease which can result in weakness and fatigue. We are excited about our first regulatory filing for daprodustat which, if approved, will provide a new and convenient oral treatment option for these patients.” | tradermichael | |
20/8/2019 09:23 | Dial 1700 for a £1 profit going long, imv! (I'm not a short term trader 'tho). | sogoesit | |
20/8/2019 09:05 | Fatal also could mean dial 999 :) | abdullla | |
20/8/2019 08:57 | "Fatal"? See your Risk Management Manual, please. ;-) | sogoesit | |
20/8/2019 08:30 | TM,with the GSK share price shooting up daily what is the future entry point for those having sold and now sitting on the cash,re-entry at this point of time could be fatal? | abdullla | |
18/8/2019 13:27 | Some divis coming my way next week (RIO). Looks like this a good candidate for accumulation. | sogoesit | |
16/8/2019 09:58 | Thanks for info TM :-) | sicker | |
16/8/2019 09:22 | Breaking: FTSE trading should partially re-commence at 10:10am The LSE says: All GTD orders on partition 1 and 2 have been expired. Instruments on partition 1 and 2 will resume in an opening auction call at 09:20 and will uncross at 09:40. EDSP auction for FTSE100 securities will commence as per today’s standard schedule at 10:10. Users that receive rejection messages, are advised to log out their trading sessions and log back on to the relevant gateways again. | tradermichael | |
16/8/2019 09:18 | Technical glitches have been blamed for previous outages with investors last left in limbo by a four-hour delay to trading in 2011, after the LSE switched from its Turquoise system to a new platform called MillenniumIT. The shutdown came on the new system's 10th day of operation. | tradermichael | |
16/8/2019 09:00 | Looking to buy in below 16.40 to add to those I already have. I'm heavy in GSK but did buy some RDSB and LGEN yesterday. Income is key for me but will take advantage of ranges when I'm confident to do so. | aimtoretire | |
16/8/2019 08:33 | Yes, London Stock Exchange delays open of top indexes after “potential trading services issue” is discovered | tradermichael | |
16/8/2019 08:32 | Cant trade either on ii so looks like a market issue | phda | |
16/8/2019 08:31 | Anybody see any prices this morning? My screens show no live data?? | tradermichael | |
15/8/2019 11:25 | Next week I reckon. | iknowverylittle |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions